| CME Provider |
Website title |
Module | CME
credits |
Expiry |
|
Academic Medical Center Amsterdam. Dept Vascular Medicine |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc |
HbA1c in CVD |
0 |
04 Jun 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc |
Hypoglycemia in CV medicine - why worry? |
0 |
04 Jun 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc |
Key classes of antidiabetic drugs |
0 |
04 Jun 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc |
Natural history of diabetes: focus on microvascular and macrovascular complications |
1 |
04 Jun 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc |
T2DM and CV outcomes |
0 |
04 Jun 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Clinical updates in management of cardiovascular risk - https://academy1745879297.coursepath.com/1706498/course-toc |
Early intervention for lifetime CV risk reduction |
1 |
07 Aug 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Clinical updates in management of cardiovascular risk - https://academy1745879297.coursepath.com/1706498/course-toc |
Estimating CV risk and treatment benefit |
0 |
07 Aug 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Clinical updates in management of cardiovascular risk - https://academy1745879297.coursepath.com/1706498/course-toc |
Importance of hypertension in CVD prevention |
0 |
07 Aug 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Clinical updates in management of cardiovascular risk - https://academy1745879297.coursepath.com/1706498/course-toc |
The role of lipids in CVD prevention: Lessons learned about statins |
0 |
07 Aug 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Contemporary management of a patient with heart failure and diabetes: Implications from recent trials - https://pace-cmelearninglab.coursepath.com/1968642/course-toc |
Current management of heart failure & T2DM |
1 |
19 Sep 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Contemporary management of a patient with heart failure and diabetes: Implications from recent trials - https://pace-cmelearninglab.coursepath.com/1968642/course-toc |
Guidance from outcome trials: What are the clinical implications |
0 |
19 Sep 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Contemporary management of a patient with heart failure and diabetes: Implications from recent trials - https://pace-cmelearninglab.coursepath.com/1968642/course-toc |
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology |
0 |
19 Sep 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Contemporary management of a patient with heart failure and diabetes: Implications from recent trials - https://pace-cmelearninglab.coursepath.com/1968642/course-toc |
Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes |
0 |
19 Sep 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Diabetes, Cardiology & Novel Therapeutic Approaches - https://pace-cmelearninglab.coursepath.com/2755074/course-toc |
Diabetes & CVD: Time for a multifactorial approach |
1 |
13 Mar 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Diabetes, Cardiology & Novel Therapeutic Approaches - https://pace-cmelearninglab.coursepath.com/2755074/course-toc |
Novel therapeutic diabetes approaches: The cardiovascular benefits beyond glucose control |
0 |
13 Mar 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Diabetes, Cardiology & Novel Therapeutic Approaches - https://pace-cmelearninglab.coursepath.com/2755074/course-toc |
Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit? |
0 |
13 Mar 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition - https://pace-cmelearninglab.coursepath.com/2099714/course-toc |
Addressing the remaining questions on SGLT2 & CKD: A review of new outcome trials |
0 |
07 Dec 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition - https://pace-cmelearninglab.coursepath.com/2099714/course-toc |
SGLT2 inhibition in kidney disease: What are the key lessons from the EMPA-REG OUTCOME trial? |
1 |
07 Dec 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition - https://pace-cmelearninglab.coursepath.com/2099714/course-toc |
Understanding CKD & SGLT2 inhibition: What are the key mechanisms for benefit? |
0 |
07 Dec 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Exploring the role of GLP-1 RA in the management of CVD & T2DM - https://pace-cmelearninglab.coursepath.com/1837570/course-toc |
Clinical trials in diabetes and CVD - What did we learn? |
0 |
10 Dec 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Exploring the role of GLP-1 RA in the management of CVD & T2DM - https://pace-cmelearninglab.coursepath.com/1837570/course-toc |
Novel diabetes drugs in clinical management: extending the opportunities |
0 |
10 Dec 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Exploring the role of GLP-1 RA in the management of CVD & T2DM - https://pace-cmelearninglab.coursepath.com/1837570/course-toc |
Translation of novel approaches in CVD & diabetes to clinical practice |
0 |
10 Dec 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Exploring the role of GLP-1 RA in the management of CVD & T2DM - https://pace-cmelearninglab.coursepath.com/1837570/course-toc |
What are the key mechanisms of CV benefit of novel diabetes drugs? |
0 |
10 Dec 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Exploring the role of GLP-1 RA in the management of CVD & T2DM - https://pace-cmelearninglab.coursepath.com/1837570/course-toc |
What is the science driving CVD and T2DM? |
1 |
10 Dec 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Novel concepts and treatments of comorbidities in heart failure with preserved ejection fraction - https://pace-cmelearninglab.coursepath.com/1903106/course-toc |
Atrial fibrillation & HFpEF: Novel device and therapeutic approaches |
0 |
19 Sep 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Novel concepts and treatments of comorbidities in heart failure with preserved ejection fraction - https://pace-cmelearninglab.coursepath.com/1903106/course-toc |
Diabetes & Obesity in HFpEF: New targets in heart failure management |
0 |
19 Sep 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Novel concepts and treatments of comorbidities in heart failure with preserved ejection fraction - https://pace-cmelearninglab.coursepath.com/1903106/course-toc |
HFpEF: from understanding the physiology to development of new treatments |
1 |
19 Sep 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Outcomes of GLP-1 RA in Diabetes & CVD: What are the key opportunities for cardiology practice? - https://pace-cmelearninglab.coursepath.com/2624002/course-toc |
Diabetes & CVD: Time for a multifactorial approach |
1 |
17 Jan 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Outcomes of GLP-1 RA in Diabetes & CVD: What are the key opportunities for cardiology practice? - https://pace-cmelearninglab.coursepath.com/2624002/course-toc |
GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control |
0 |
17 Jan 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Outcomes of GLP-1 RA in Diabetes & CVD: What are the key opportunities for cardiology practice? - https://pace-cmelearninglab.coursepath.com/2624002/course-toc |
Translating GLP-1 trial outcomes to cardiology practice: Which patients will benefit? |
0 |
17 Jan 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
PCSK9 inhibition: Science, outcomes & guidance - https://pace-cmelearninglab.coursepath.com/2558466/course-toc |
Introduction |
1 |
22 Feb 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
PCSK9 inhibition: Science, outcomes & guidance - https://pace-cmelearninglab.coursepath.com/2558466/course-toc |
Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY |
0 |
22 Feb 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
PCSK9 inhibition: Science, outcomes & guidance - https://pace-cmelearninglab.coursepath.com/2558466/course-toc |
PCSK9 as target for treatment: The genetic validation |
0 |
22 Feb 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
PCSK9 inhibition: Science, outcomes & guidance - https://pace-cmelearninglab.coursepath.com/2558466/course-toc |
Targeting PCSK9 in clinical practice: Guidance & future |
0 |
22 Feb 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
PCSK9: Outcomes and trials in clinical perspective - https://pace-cmelearninglab.coursepath.com/2689538/course-toc |
Guidelines and the role of non-statin therapies for high risk ASCVD patients |
0 |
22 Feb 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
PCSK9: Outcomes and trials in clinical perspective - https://pace-cmelearninglab.coursepath.com/2689538/course-toc |
Identifying patients for PCSK9 therapy |
1 |
22 Feb 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
PCSK9: Outcomes and trials in clinical perspective - https://pace-cmelearninglab.coursepath.com/2689538/course-toc |
Landmark trials with PCSK9 inhibitors |
0 |
22 Feb 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
PCSK9: Outcomes and trials in clinical perspective - https://pace-cmelearninglab.coursepath.com/2689538/course-toc |
PCSK9 inhibitors: How do they work? |
0 |
22 Feb 2021 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Preventing cardiovascular disease in patients with T2DM - The role of GLP-1 RA - https://pace-cmelearninglab.coursepath.com/1772034/course-toc |
Diabetes: How to reduce risk from a cardiovascular perspective? |
0 |
23 Aug 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Preventing cardiovascular disease in patients with T2DM - The role of GLP-1 RA - https://pace-cmelearninglab.coursepath.com/1772034/course-toc |
Practical management of cardiovascular risk: Lessons from latest diabetes trials |
0 |
23 Aug 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Preventing cardiovascular disease in patients with T2DM - The role of GLP-1 RA - https://pace-cmelearninglab.coursepath.com/1772034/course-toc |
The cardiovascular challenge for primary care in diabetes |
1 |
23 Aug 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Pulmonary arterial hypertension - key questions addressed - https://pace-cmelearninglab.coursepath.com/1640962/course-toc |
Diagnosis, classification of patients, prognosis |
0 |
23 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Pulmonary arterial hypertension - key questions addressed - https://pace-cmelearninglab.coursepath.com/1640962/course-toc |
Future perspectives |
0 |
23 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Pulmonary arterial hypertension - key questions addressed - https://pace-cmelearninglab.coursepath.com/1640962/course-toc |
Treatment options, follow-up of non-responsive patients, optimization of therapy |
0 |
23 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Pulmonary arterial hypertension - key questions addressed - https://pace-cmelearninglab.coursepath.com/1640962/course-toc |
Underlying pathophysiology, characteristics, clinical subgroups, prevalence and risk factors |
1 |
23 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Targeting residual risk with anti-inflammatory therapies - https://pace-cmelearninglab.coursepath.com/1575426/course-toc |
Inflammation & CVD: Translating insights from vascular biology to the clinic |
0 |
07 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Targeting residual risk with anti-inflammatory therapies - https://pace-cmelearninglab.coursepath.com/1575426/course-toc |
The CANTOS trial: Implications for the management of patients with residual risk |
0 |
07 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Targeting residual risk with anti-inflammatory therapies - https://pace-cmelearninglab.coursepath.com/1575426/course-toc |
The new era of residual risk reduction |
0 |
07 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Targeting residual risk with anti-inflammatory therapies - https://pace-cmelearninglab.coursepath.com/1575426/course-toc |
The patient with inflammatory residual risk: Who is it? |
1 |
07 May 2020 |
|
Asian Pacific Society of Cardiology |
| Asian Pacific Society of Cardiology/ J. Tan |
GDF-15 and risk stratification in Atrial Fibrillation - https://event.on24.com/wcc/r/1773686/09ACB1305E44D118152C638A49141637 |
GDF-15 and new ABC-AF risk score in atrial fibrillation |
1 |
16 Jul 2021 |
|
British Heart Rhythm Society |
| British Heart Rhythm Society/ J. Gill |
https://www.radcliffe-cme.com; Programme title: Convergent procedure: A new approach to atrial fibrillation ablation - https://www.radcliffe-cme.com/content/convergent-procedure-new-approach-atrial-fibrillation-ablation#group-tabs-node-course-default1 |
Convergent ablation: The what and the why |
0 |
27 Jun 2021 |
| British Heart Rhythm Society/ J. Gill |
https://www.radcliffe-cme.com; Programme title: Convergent procedure: A new approach to atrial fibrillation ablation - https://www.radcliffe-cme.com/content/convergent-procedure-new-approach-atrial-fibrillation-ablation#group-tabs-node-course-default1 |
The electrophysiologic problem leading to sub-optimal outcomes |
0 |
27 Jun 2021 |
| British Heart Rhythm Society/ J. Gill |
https://www.radcliffe-cme.com; Programme title: Convergent procedure: A new approach to atrial fibrillation ablation - https://www.radcliffe-cme.com/content/convergent-procedure-new-approach-atrial-fibrillation-ablation#group-tabs-node-course-default1 |
The ongoing challenges of atrial fibrillation |
1 |
27 Jun 2021 |
| British Heart Rhythm Society/ J. Gill |
https://www.radcliffe-cme.com; Programme title: Convergent procedure: A new approach to atrial fibrillation ablation - https://www.radcliffe-cme.com/content/convergent-procedure-new-approach-atrial-fibrillation-ablation#group-tabs-node-course-default1 |
The role of the electrophysiologist in convergent ablation: The how and the who |
0 |
27 Jun 2021 |
|
Dept of Cardiac, thoracic and Vascular Science, University of Padua, Italy |
| Dept of Cardiac, thoracic and Vascular Science, University of Padua, Italy/ L. Badano |
How 3D Echocardiography has changed the way we look at valves using ultrasounds - http://3decho360.com/elearning/ |
Basic principles of 3D echocardiography |
1 |
22 Jan 2022 |
| Dept of Cardiac, thoracic and Vascular Science, University of Padua, Italy/ L. Badano |
How 3D Echocardiography has changed the way we look at valves using ultrasounds - http://3decho360.com/elearning/ |
New anatomical and pathophysiological insights in tricuspid regurgitation |
0 |
22 Jan 2022 |
| Dept of Cardiac, thoracic and Vascular Science, University of Padua, Italy/ L. Badano |
How 3D Echocardiography has changed the way we look at valves using ultrasounds - http://3decho360.com/elearning/ |
Quantitative assessment of the aortic valve |
0 |
22 Jan 2022 |
| Dept of Cardiac, thoracic and Vascular Science, University of Padua, Italy/ L. Badano |
How 3D Echocardiography has changed the way we look at valves using ultrasounds - http://3decho360.com/elearning/ |
Value of 3D Echo for the assessment of the Mitral Valve |
0 |
22 Jan 2022 |
|
EXCEMED |
| EXCEMED/ S. Taddei |
Interactive clinical case: Heart failure - https://www.excemed.org/user/login?destination=excemedlearning/67 |
Interactive clinical case: Heart failure |
1 |
20 Nov 2020 |
|
International Society of Cardiovascular Pharmacotherapy |
| International Society of Cardiovascular Pharmacotherapy/ A. Coats |
A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref |
ARIADNE in Review |
0 |
26 Nov 2021 |
| International Society of Cardiovascular Pharmacotherapy/ A. Coats |
A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref |
Commentary on ARIADNE Trial |
0 |
26 Nov 2021 |
| International Society of Cardiovascular Pharmacotherapy/ A. Coats |
A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref |
Commentary on PROVE-HF and EVALUATE-HF Trials |
0 |
26 Nov 2021 |
| International Society of Cardiovascular Pharmacotherapy/ A. Coats |
A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref |
Commentary on the TRANSITION-CHF and PIONEER Trials |
0 |
26 Nov 2021 |
| International Society of Cardiovascular Pharmacotherapy/ A. Coats |
A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref |
Conclusions |
0 |
26 Nov 2021 |
| International Society of Cardiovascular Pharmacotherapy/ A. Coats |
A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref |
EVALUATE-HF in Review |
0 |
26 Nov 2021 |
| International Society of Cardiovascular Pharmacotherapy/ A. Coats |
A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref |
PIONEER in Review |
0 |
26 Nov 2021 |
| International Society of Cardiovascular Pharmacotherapy/ A. Coats |
A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref |
PROVE-HF in Review |
0 |
26 Nov 2021 |
| International Society of Cardiovascular Pharmacotherapy/ A. Coats |
A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref |
TRANSITION-CHF in Review |
0 |
26 Nov 2021 |
| International Society of Cardiovascular Pharmacotherapy/ A. Coats |
A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref |
Welcome and Introduction |
1 |
26 Nov 2021 |
| International Society of Cardiovascular Pharmacotherapy/ F. Martinez |
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure - https://www.radcliffeeducation.com/content/current-and-emerging-data-sglt2-inhibitors-heart-failure#group-tabs-node-course-default1 |
Current Guidelines, Recent Data, and Future Practices |
0 |
29 Dec 2021 |
| International Society of Cardiovascular Pharmacotherapy/ F. Martinez |
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure - https://www.radcliffeeducation.com/content/current-and-emerging-data-sglt2-inhibitors-heart-failure#group-tabs-node-course-default1 |
DAPA-HF - Clinical Trial Design Rationale |
0 |
29 Dec 2021 |
| International Society of Cardiovascular Pharmacotherapy/ F. Martinez |
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure - https://www.radcliffeeducation.com/content/current-and-emerging-data-sglt2-inhibitors-heart-failure#group-tabs-node-course-default1 |
DAPA-HF - Interview with the Trialist |
0 |
29 Dec 2021 |
| International Society of Cardiovascular Pharmacotherapy/ F. Martinez |
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure - https://www.radcliffeeducation.com/content/current-and-emerging-data-sglt2-inhibitors-heart-failure#group-tabs-node-course-default1 |
SGLT2 in HF - Now and in the Future |
0 |
29 Dec 2021 |
| International Society of Cardiovascular Pharmacotherapy/ F. Martinez |
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure - https://www.radcliffeeducation.com/content/current-and-emerging-data-sglt2-inhibitors-heart-failure#group-tabs-node-course-default1 |
SGLT2i Beyond Diabetes - Mechanism of Benefit in CVD |
0 |
29 Dec 2021 |
| International Society of Cardiovascular Pharmacotherapy/ F. Martinez |
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure - https://www.radcliffeeducation.com/content/current-and-emerging-data-sglt2-inhibitors-heart-failure#group-tabs-node-course-default1 |
Summary and Conclusions |
0 |
29 Dec 2021 |
| International Society of Cardiovascular Pharmacotherapy/ F. Martinez |
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure - https://www.radcliffeeducation.com/content/current-and-emerging-data-sglt2-inhibitors-heart-failure#group-tabs-node-course-default1 |
The Dapaglifozin and Prevention of Adverse Outcomes in HF Trial |
0 |
29 Dec 2021 |
| International Society of Cardiovascular Pharmacotherapy/ F. Martinez |
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure - https://www.radcliffeeducation.com/content/current-and-emerging-data-sglt2-inhibitors-heart-failure#group-tabs-node-course-default1 |
Welcome and Introduction |
1 |
29 Dec 2021 |
|
Maastricht University Medical Center |
| Maastricht University Medical Center/ H. Crijns |
Radcliffe CME - https://www.radcliffe-cme.com/user/login?destination=homepage |
Case study: Successful AF ablation program - perils, pitfalls and tricks |
0 |
17 May 2020 |
| Maastricht University Medical Center/ H. Crijns |
Radcliffe CME - https://www.radcliffe-cme.com/user/login?destination=homepage |
Introduction: What is the value of a multidisciplianry AF Heart Team? |
1 |
17 May 2020 |
| Maastricht University Medical Center/ H. Crijns |
Radcliffe CME - https://www.radcliffe-cme.com/user/login?destination=homepage |
What are the practical considerations for implementing a MDT Heart Team in your hospital? |
0 |
17 May 2020 |
| Maastricht University Medical Center/ H. Crijns |
Radcliffe CME - https://www.radcliffe-cme.com/user/login?destination=homepage |
What evidence exists to support hybrid ablation? |
0 |
17 May 2020 |
|
PACE-CME |
| PACE-CME/ J. Kastelein |
Impacting progression and outcomes of DKD: Translating novel insights with GLP-1RA to practice - https://pace-cmelearninglab.coursepath.com/3148290/course-toc |
Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials |
0 |
02 Jan 2022 |
| PACE-CME/ J. Kastelein |
Impacting progression and outcomes of DKD: Translating novel insights with GLP-1RA to practice - https://pace-cmelearninglab.coursepath.com/3148290/course-toc |
Importance of protection and prevention in cardiorenal disease |
1 |
02 Jan 2022 |
| PACE-CME/ J. Kastelein |
Impacting progression and outcomes of DKD: Translating novel insights with GLP-1RA to practice - https://pace-cmelearninglab.coursepath.com/3148290/course-toc |
The science behind vascular and renal benefits of GLP-1 receptor agonists |
0 |
02 Jan 2022 |
| PACE-CME/ J. Kastelein |
LDL-c lowering in high CV risk patients - https://pace-cmelearninglab.coursepath.com/2820610/course-toc |
Are very low LDL-c levels safe? |
0 |
12 Jul 2021 |
| PACE-CME/ J. Kastelein |
LDL-c lowering in high CV risk patients - https://pace-cmelearninglab.coursepath.com/2820610/course-toc |
Challenges for screening and treatment of FH patients in clinical cardiology |
0 |
12 Jul 2021 |
| PACE-CME/ J. Kastelein |
LDL-c lowering in high CV risk patients - https://pace-cmelearninglab.coursepath.com/2820610/course-toc |
Cholesterol guidelines in need of major changes? |
0 |
12 Jul 2021 |
| PACE-CME/ J. Kastelein |
LDL-c lowering in high CV risk patients - https://pace-cmelearninglab.coursepath.com/2820610/course-toc |
How are the guidelines for progressive CAD guiding us in clinical practice? |
0 |
12 Jul 2021 |
| PACE-CME/ J. Kastelein |
LDL-c lowering in high CV risk patients - https://pace-cmelearninglab.coursepath.com/2820610/course-toc |
LDL-c as target in cardiology: the road towards lower targets |
1 |
12 Jul 2021 |
| PACE-CME/ J. Kastelein |
LDL-c lowering in high CV risk patients - https://pace-cmelearninglab.coursepath.com/2820610/course-toc |
Progressive CAD despite low LDL-c, an elusive disease? |
0 |
12 Jul 2021 |
| PACE-CME/ J. Kastelein |
LDL-c lowering in high CV risk patients - https://pace-cmelearninglab.coursepath.com/2820610/course-toc |
What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol? |
0 |
12 Jul 2021 |
| PACE-CME/ J. Kastelein |
PCSK9i, changing practice in cardiology: The emerging story - https://pace-cmelearninglab.coursepath.com/3017218/course-toc |
Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients? |
0 |
09 Dec 2021 |
| PACE-CME/ J. Kastelein |
PCSK9i, changing practice in cardiology: The emerging story - https://pace-cmelearninglab.coursepath.com/3017218/course-toc |
Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most? |
1 |
09 Dec 2021 |
| PACE-CME/ J. Kastelein |
PCSK9i, changing practice in cardiology: The emerging story - https://pace-cmelearninglab.coursepath.com/3017218/course-toc |
Targeting PCSK9: Expanding knowledge and targeting new frontiers |
0 |
09 Dec 2021 |
| PACE-CME/ A. Voors |
RAASi and Hyperkalemia in Cardiorenal Disease: Opportunities for optimizing outcomes - https://pace-cmelearninglab.coursepath.com/2886146/course-toc |
Addressing the risk of hyperkalemia: is there a sweet spot for potassium binding? |
0 |
23 Oct 2021 |
| PACE-CME/ A. Voors |
RAASi and Hyperkalemia in Cardiorenal Disease: Opportunities for optimizing outcomes - https://pace-cmelearninglab.coursepath.com/2886146/course-toc |
Managing hyperkalemia in cardiorenal patients: Novel therapeutic insights to optimize outcomes |
0 |
23 Oct 2021 |
| PACE-CME/ A. Voors |
RAASi and Hyperkalemia in Cardiorenal Disease: Opportunities for optimizing outcomes - https://pace-cmelearninglab.coursepath.com/2886146/course-toc |
RAAS inhibition in patients with kidney disease: balancing the benefits and risks |
1 |
23 Oct 2021 |
| PACE-CME/ A. Voors |
Reshaping the future of heart failure management - Translating innovations to practice in HFpEF - https://pace-cmelearninglab.coursepath.com/2951682/course-toc |
Cardiac amyloidosis: An emerging target in HFpEF? |
0 |
30 Jan 2022 |
| PACE-CME/ A. Voors |
Reshaping the future of heart failure management - Translating innovations to practice in HFpEF - https://pace-cmelearninglab.coursepath.com/2951682/course-toc |
Heart failure & diabetes: What is the goal of treatment? |
0 |
30 Jan 2022 |
| PACE-CME/ A. Voors |
Reshaping the future of heart failure management - Translating innovations to practice in HFpEF - https://pace-cmelearninglab.coursepath.com/2951682/course-toc |
Understanding and managing obesity-related HFpEF |
1 |
30 Jan 2022 |
| PACE-CME/ A. Voors |
SGLT2 inhibition in CKD: Discussing the key questions and evidence - https://pace-cmelearninglab.coursepath.com/3082754/course-toc |
Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes? |
1 |
18 Dec 2021 |
| PACE-CME/ A. Voors |
SGLT2 inhibition in CKD: Discussing the key questions and evidence - https://pace-cmelearninglab.coursepath.com/3082754/course-toc |
The clinical landscape of managing patients with CKD: Where are we now and what can we expect? |
0 |
18 Dec 2021 |
| PACE-CME/ A. Voors |
SGLT2 inhibition in CKD: Discussing the key questions and evidence - https://pace-cmelearninglab.coursepath.com/3082754/course-toc |
Underlying mechanisms of nephroprotective effects with SGLT2i in CKD |
0 |
18 Dec 2021 |
|
University Medical Center Groningen |
| University Medical Center Groningen/ A. Voors |
HFpEF: The essentials to know - https://pace-cmelearninglab.coursepath.com/2492930/course-toc |
Current and future clinical approaches to manage HFpEF |
0 |
22 Feb 2021 |
| University Medical Center Groningen/ A. Voors |
HFpEF: The essentials to know - https://pace-cmelearninglab.coursepath.com/2492930/course-toc |
HFpEF: How to diagnose |
0 |
22 Feb 2021 |
| University Medical Center Groningen/ A. Voors |
HFpEF: The essentials to know - https://pace-cmelearninglab.coursepath.com/2492930/course-toc |
HFpEF: What are the most likely pathophysiological mechanisms involved in the disease |
0 |
22 Feb 2021 |
| University Medical Center Groningen/ A. Voors |
HFpEF: The essentials to know - https://pace-cmelearninglab.coursepath.com/2492930/course-toc |
HFpEF: What is it & size of the problem |
1 |
22 Feb 2021 |
|
UpToDate |
| UpToDate/ T. Post |
UpToDate - https://www.uptodate.com |
UpToDate |
1 |
29 Jan 2021 |
